首页> British journal of haematology> The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.

导出 LinkOut

翻译打印收藏纠错

第一作者： Giulio,Sartori

第一单位： Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

作者： Giulio,Sartori ^[1] ; Chiara,Tarantelli ^[1] ; Filippo,Spriano ^[1] ; Eugenio,Gaudio ^[1] ; Luciano,Cascione ^[2] ; Michele,Mascia ^[1] ; Marilia,Barreca ^[3] ; Alberto J,Arribas ^[2] ; Luca,Licenziato ^[4] ; Gaetanina,Golino ^[1] ; Adele,Ferragamo ^[1] ; Stefano,Pileri ^[5] ; Giovanna,Damia ^[6] ; Emanuele,Zucca ^[7] ; Anastasios,Stathis ^[8] ; Oliver,Politz ^[9] ; Antje M,Wengner ^[9] ; Francesco,Bertoni ^[7]

作者单位： Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland. ^[1] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. ^[2] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy. ^[3] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;Department of Veterinary Sciences, University of Turin, Turin, Italy. ^[4] Division of Diagnostic Haematopathology, European Institute of Oncology, Milan, Italy. ^[5] Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. ^[6] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. ^[7] Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Faculty of Biomedical Sciences, USI, Lugano, Switzerland. ^[8] Bayer AG, Pharmaceuticals, Research & Development, Berlin, Germany. ^[9]

关键词 ATR CDKN2A DDR PI3K lymphoma

医学主题词人类(Humans);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);蛋白激酶抑制剂(Protein Kinase Inhibitors);肿瘤(Neoplasms);淋巴瘤(Lymphoma);DNA损伤(DNA Damage)

DOI 10.1111/bjh.19218

PMID 38011941

发布时间 2024-03-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交